Coronavirus • 14 April, 2021

Health Ministry: Kazakhstan’s subunit vaccine ready for clinical trials

1 time viewed

The subunit vaccine against COVID-19 developed by Kazakhstani scientists is ready for clinical trials, reports.

According to Vice-Minister of Education and Science, several COVID-19 vaccines are being developed at the Research Institute for Biological Safety Problems, including the subunit (recombinant) vaccine, which is ready to enter clinical trials.

The trials will begin after the authorization of the Health Ministry. They also highlighted, the Institute is working on a polyvalent vaccine, with the British and South African variants being closely studied for updating vaccines.

Notably, the Research Institute for Biological Safety Problems is developing five COVID-19 vaccines, including the inactive QazCOVID-in vaccine, two vector vaccines, an attenuated vaccine and a subunit vaccine. Earlier it was reported that phase 3 of the clinical trials of Kazakhstan’s QazCovid-in will be 50% complete on April 15.


Last news

New deputy mayor of Almaty named

Appointment • 11 May, 2021

Chairman of the Senate defeat COVID-19

Government • 11 May, 2021

President receives Aruzhan Sain

President • 05 May, 2021

President receives National Bank Chairman

President • 05 May, 2021

9 areas still in «red zone» in Kazakhstan

Coronavirus • 05 May, 2021

Elbasy’s new Chief of Protocol named

Government • 05 May, 2021

8 regions of Kazakhstan remain in «red zone»

Coronavirus • 30 April, 2021

Elbasy highlights importance of state language

Елбасы • 28 April, 2021

Similar news